<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604744</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC 2018-00985</org_study_id>
    <nct_id>NCT03604744</nct_id>
  </id_info>
  <brief_title>Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin</brief_title>
  <acronym>LSD-psilo</acronym>
  <official_title>Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin in a Random-order Placebo-controlled Cross-over Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LSD (lysergic acid diethylamide) and psilocybin (the active substance in &quot;magic mushrooms&quot;)
      are widely used for recreational purposes. Both substances are also increasingly used in
      psychiatric and psychological research to induce and investigate alterations in waking
      consciousness and associated brain functions (functional brain imaging, &quot;model psychosis&quot;) .
      However, it has never been studied whether there are differences in the alterations in mind
      produced by these two substances. Both LSD and psilocybin are thought to induce
      hallucinations primarily via stimulation of the 5-HT2A receptor. However, there are
      differences in the receptor activation profiles between the two substances that may also
      induce different subjective effects. LSD potently stimulates the 5-HT2A receptor but also
      5-HT2B/C, 5-HT1 and D1-3 receptors . Psilocin (the active metabolite of the prodrug
      psilocybin) also stimulates the 5-HT2A receptor but additionally inhibits the 5-HT
      transporter. In contrast to LSD, psilocybin has no affinity for D2 receptors. Both substances
      are used in neuroscience as pharmacological tools. However, there are no modern studies
      comparing these two substances directly within the same clinical study and research subjects
      and using validated psychometric tools. Therefore, the investigators will compare the acute
      effects of LSD, psilocybin and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Altered states of consciousness</measure>
    <time_frame>18 Months</time_frame>
    <description>total 5D-ASC score (5-Dimensional Altered States of Consciousness Rating Scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective effects assessed by VAS</measure>
    <time_frame>18 Months</time_frame>
    <description>VAS (Visual analog scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective effects assessed by AMRS scales</measure>
    <time_frame>18 Months</time_frame>
    <description>AMRS scales (Adjective mood Rating scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychotomimetic effects</measure>
    <time_frame>18 Months</time_frame>
    <description>ESI (Eppendorf Schizophrenia Inventory)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mystical-type experiences assessed by SCQ</measure>
    <time_frame>18 Months</time_frame>
    <description>SCQ (States of consciousness questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mystical-type experiences assessed by MS scales</measure>
    <time_frame>18 Months</time_frame>
    <description>MS scales (Mysticism scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on emotion processing</measure>
    <time_frame>18 Months</time_frame>
    <description>FERT (Face Emotion Recognition Task)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects assessed by heart rate</measure>
    <time_frame>18 Months</time_frame>
    <description>Heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects assessed by blood pressure</measure>
    <time_frame>18 Months</time_frame>
    <description>Blood pressure (diastolic and systolic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects assessed by body temperature</measure>
    <time_frame>18 Months</time_frame>
    <description>Body temperature</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma levels of LSD and psilocin</measure>
    <time_frame>18 Months</time_frame>
    <description>assessment of plasma levels of LSD and psilocin</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LSD</intervention_name>
    <description>LSD 0.1 mg per os, single dose</description>
    <arm_group_label>LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo</arm_group_label>
    <arm_group_label>LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100</arm_group_label>
    <arm_group_label>Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30</arm_group_label>
    <arm_group_label>Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200</arm_group_label>
    <arm_group_label>Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LSD</intervention_name>
    <description>LSD 0.2 mg per os, single dose</description>
    <arm_group_label>LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo</arm_group_label>
    <arm_group_label>LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100</arm_group_label>
    <arm_group_label>Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30</arm_group_label>
    <arm_group_label>Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200</arm_group_label>
    <arm_group_label>Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>Psilocybin 15 mg per os, single dose</description>
    <arm_group_label>LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo</arm_group_label>
    <arm_group_label>LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100</arm_group_label>
    <arm_group_label>Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30</arm_group_label>
    <arm_group_label>Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200</arm_group_label>
    <arm_group_label>Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>Psilocybin 30 mg per os, single dose</description>
    <arm_group_label>LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo</arm_group_label>
    <arm_group_label>LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100</arm_group_label>
    <arm_group_label>Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30</arm_group_label>
    <arm_group_label>Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200</arm_group_label>
    <arm_group_label>Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 25 and 65 years.

          2. Understanding of the German language.

          3. Understanding the procedures and the risks that are associated with the study.

          4. Participants must be willing to adhere to the protocol and sign the consent form.

          5. Participants must be willing to refrain from taking illicit psychoactive substances
             during the study.

          6. Participants must be willing to drink only alcohol-free liquids and no coffee, black
             or green tea, or energy drink after midnight of the evening before the study session,
             as well as during the study day.

          7. Participants must be willing not to drive a traffic vehicle or to operate machines
             within 48 h after substance administration.

          8. Women of childbearing potential must have a negative pregnancy test at the beginning
             of the study. Pregnancy tests are repeated before each study session.

          9. Women of childbearing potential must be willing to use double-barrier birth control

         10. Body mass index 18-29 kg/m2.

        Exclusion Criteria:

          1. Chronic or acute medical condition

          2. Current or previous major psychiatric disorder

          3. Psychotic disorder in first-degree relatives

          4. Illicit substance use (with the exception of cannabis) more than 10 times or any time
             within the previous two months.

          5. Pregnant or nursing women.

          6. Participation in another clinical trial (currently or within the last 30 days)

          7. Use of medications that may interfere with the effects of the study medications (any
             psychiatric medications)

          8. Tobacco smoking (&gt;10 cigarettes/day)

          9. Consumption of alcoholic drinks (&gt;10/week)

         10. Bodyweight &lt; 50 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias E Liechti, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias E Liechti, MD, MAS</last_name>
    <phone>61 328 68 68</phone>
    <phone_ext>+41</phone_ext>
    <email>matthias.liechti@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Friederike Holze, MSc</last_name>
    <phone>61 556 54 37</phone>
    <phone_ext>+41</phone_ext>
    <email>friederike.holze@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Pharmacology &amp; Toxicology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias E Liechti, Prof.Dr.med.</last_name>
      <phone>+41 61 265 88 68</phone>
      <phone_ext>+41</phone_ext>
      <email>matthias.liechti@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Friederike Holze, MSc</last_name>
      <phone>+41 61 556 54 37</phone>
      <phone_ext>+41</phone_ext>
      <email>friederike.holze@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias E Liechti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psilocybin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

